Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients

Ilaria Durosini, Rosanne Janssens*, Reinhard Arnou, Jorien Veldwijk, Meredith Y. Smith, Dario Monzani, Ian Smith, Giulia Galli, Marina Garassino, Eva G. Katz, Luca Bailo, Evelyne Louis, Marie Vandevelde, Kristiaan Nackaerts, G. Ardine de Wit, Gabriella Pravettoni, Isabelle Huys

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Introduction: Lung cancer is the deadliest and most prevalent cancer worldwide. Lung cancer treatments have different characteristics and are associated with a range of benefits and side effects for patients. Such differences may raise uncertainty among drug developers, regulators, payers, and clinicians regarding the value of these treatment effects to patients. The value of conducting patient preference studies (using qualitative and/or quantitative methods) for benefits and side effects of different treatment options has been recognized by healthcare stakeholders, such as drug developers, regulators, health technology assessment bodies, and clinicians. However, evidence-based guidelines on how and when to conduct and use these studies in drug decision-making are lacking. As part of the Innovative Medicines Initiative PREFER project, we developed a protocol for a qualitative study that aims to understand which treatment characteristics are most important to lung cancer patients and to develop attributes and levels for inclusion in a subsequent quantitative preference survey. Methods: The study protocol specifies a four-phased approach: (i) a scoping literature review of published literature, (ii) four focus group discussions with stage III and IV Non-Small Cell Lung Cancer patients, (iii) two nominal group discussions with stage III and IV Non-Small Cell Lung Cancer patients, and (iv) multi-stakeholder discussions involving clinicians and preference experts. Discussion: This protocol outlines methodological and practical steps as to how qualitative research can be applied to identify and develop attributes and levels for inclusion in patient preference studies aiming to inform decisions across the drug life cycle. The results of this study are intended to inform a subsequent quantitative preference survey that assesses patient trade-offs regarding lung cancer treatment options. This protocol may assist researchers, drug developers, and decision-makers in designing qualitative studies to understand which treatment aspects are most valued by patients in drug development, regulation, and reimbursement.

Original languageEnglish
Article number622154
JournalFrontiers in Public Health
Volume9
DOIs
Publication statusPublished - 5 Feb 2021

Bibliographical note

Funding Information:
Funding. This study is part of the PREFER project. The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement N. 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Publisher Copyright:
© Copyright © 2021 Durosini, Janssens, Arnou, Veldwijk, Smith, Monzani, Smith, Galli, Garassino, Katz, Bailo, Louis, Vandevelde, Nackaerts, de Wit, Pravettoni and Huys.

Copyright © 2021 Durosini, Janssens, Arnou, Veldwijk, Smith, Monzani, Smith, Galli, Garassino, Katz, Bailo, Louis, Vandevelde, Nackaerts, de Wit, Pravettoni and Huys.

Fingerprint

Dive into the research topics of 'Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients'. Together they form a unique fingerprint.

Cite this